August 25, 2022
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Attn: Conlon Danberg
| Re: | HCW Biologics Inc. |
| Registration Statement on Form S-3 |
| File No. 333-266991 |
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, HCW Biologics Inc. (the “Company”) hereby requests that the U.S. Securities and Exchange Commission (the “Commission”) take appropriate action to declare the above-referenced Registration Statement on Form S-3 to become effective on Friday, August 26, 2022, at 4:00 p.m., Eastern Time, or as soon as practicable thereafter.
The Company hereby authorizes William L. Hughes of Orrick, Herrington & Sutcliffe LLP, counsel to the Company, to orally modify or withdraw this request for acceleration.
The Company requests that it be notified of such effectiveness by a telephone call to William L. Hughes of Orrick, Herrington & Sutcliffe LLP at (415) 773-5720.
| Very truly yours, | ||
| HCW BIOLOGICS INC. | ||
| By: | /s/ Hing C. Wong | |
| Name: | Hing C. Wong, Ph.D. | |
| Title: | Chief Executive Officer and Director | |
| cc: | William L. Hughes, Orrick, Herrington & Sutcliffe LLP |